Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues – Tripeptides – e.g. – tripeptide thyroliberin – etc.
Reexamination Certificate
2007-12-25
2007-12-25
Lukton, David (Department: 1654)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
Tripeptides, e.g., tripeptide thyroliberin , etc.
C514S018700, C514S019300
Reexamination Certificate
active
10606422
ABSTRACT:
The invention is directed to substituted heterocyclic acyl-tripeptides useful as thrombin receptor modulators, their use in wound healing and preventing platelet aggregation. Pharmaceutical compositions comprising the substituted heterocyclic acyl-tripeptides of the present invention and methods of treating conditions mediated by the thrombin receptor are also disclosed.
REFERENCES:
patent: 4314936 (1982-02-01), Yaron et al.
patent: 5391705 (1995-02-01), Neises et al.
patent: 5696231 (1997-12-01), Abelman et al.
patent: 6017890 (2000-01-01), Oekstra et al.
patent: 6069232 (2000-05-01), Malikayl et al.
patent: 0503203 (1992-09-01), None
patent: 9201875 (1992-06-01), None
patent: 9901290 (1999-11-01), None
patent: WO92/04371 (1992-03-01), None
patent: WO99/42475 (1999-08-01), None
Cindy L. A. Jones, “Responese of a human megakaryocytic cell line to thrombin: Increase in Intracellular free calcium and mitogen release”, Biochimica et Biophysica Acta, 1136 (1992) 272-282.
Hoekstra, W.J. et al., “Thrombin Receptor (PAR-1) Antagonists. Heterocycle-based peptidomimetics of the SFLLR agonist motif”, Biorganic & Medical Chemistry Letters, GB, Oxford, vol. 8, No. 13, Jul. 7, 1998, pp. 1649-1654.
Bernatowicz E.A., “Development of potent thrombin receptor antagonist peptides”, Journal of Medicinal Chemistry, vol. 39, 1996, pp. 4879-4887.
McComsey, D.F. et al., “Heterocycle-peptide hybrid compounds. Aminotriazole-containing agonists of the thrombin receptor (PAR-1)”, Bioorganic & Medicinal Chemistry Letters, GB, Oxford, vol. 9, No. 10, May 17, 1999, pp. 1423-1428.
Yasuo Sugama et al., “Thrombin-Induced Expression of Endothelial P-Selection and Intercellular Adhesion Molecule-1: A Mechanism for Stabilizing Neutrophil Adhesion”, The Journal of Cell Biology, vol. 119, No. 4, Nov. 1992, pp. 935-944.
Thien-Khal & H. Vu et al., “Molecular Cloning of a Functional Thrombin Receptor Reveals a Novel Proteolytic Mechanism of Receptor Activation”, Cell, vol. 64, Mar. 1991, pp. 1057-1068.
Dimitris N. Tatakis et al., “Thrombin Effects on Osteoblastic Cells—II. Structure-Function Relastionships”, Biochemical and Biophysical Research Communications, vol. 174, No. 1, Jan. 1991, pp. 181-188.
Linde et al, “Pharmacological treatment for prevention of restenosis” Expert Opinion, 2001, pp. 281-302, Ashley Publications, www.ashley-pub.com, Canada.
Ischinger, Thomas, “Antithrombotics in Interventional Cardiology: Optimizing Treatment and Strategies”, 1998, pp. 25L-28L, vol. 28 (5B), Excerpta Medica, Inc., The American Journal of Cardiology.
Schwartz, Robert, “Pathophysiology of Restenosis: Interaction of Thrombosis, Hyperplasia, and/or Remodeling”, Excerpta Medica, Inc., A Symposium: International Vascular Medicine, 1998, pp. 14E-17E.
Marx et al, “Rampamycin-FKBP Inhibits Cell Cycle Regulators of Proliferation in Vascular Smooth Muscle Cells” Circulation Research, 1995 American Heart Association, Inc. 1995, vol. 76, pp. 412-417.
Sollott et al, “Taxol Inhibits Neointimal Smooth Muscle Cell Accumulation After Angioplasty in the Rat” The Journal of Clinical Investigation, Inc., Apr. 1995, pp.1869-1876, The Journal of Clinical Investigation, Inc., vol. 95, pp. 1869-1876.
Suzuki et al, “Stent-Based Delivery of Sirolimus Reduces Neointimal Formation in a Porcine Coronary Model” 2001 American Heart Association, pp. 1188-1193, USA.
Andrade-Gordon et al, “Adminstration of a Potent Antagonist of Protease-Activated Receptor-1 (PAR-1) Attenuates Vascular Restenosis Following Balloon Angioplasty in Rats” , The Journal of Pharmacology and Experimental Therapeutics, 2001, 298: No. 1, pp. 34-42, USA.
Chesebro et al, “Antithrombotic Therapy and Progression of Coronary Artery Disease, Antiplatelet vs. Antithrombins”, Circulation, 1992, 86[suppl III]: III-100-III-111.
White, Harvey, “Newer Antiplatelet Agents in Acute Coronary Syndromes” Cardiology Dept. Green Lane Hospital, New Zealand, e-mail; harveyw@ahsl.co.nz, 1999, Mosby, Inc.
Verstraete et al, “Novel Antithrombotic Drugs in Development”, Center for Molecular and Vascular Biology, University of Leuven, Belgium, Drugs, 1995, pp. 856-884, Adis International Limited.
Weksler, Babette, “Antiplatelet Agents in Stroke Prevention” Dept. of Medicine, New York Presbyterian Hospital—Weill Cornell Medical Center, New York, NY USA, 2000; 10(suppl 5) 41-48, www.karger.com/journals/ced.
Mousa, Shaker, “Antiplatelet therapies: from aspirin to GPllb/llla-receptor antagonists and beyond”, Therapeutic Focus, Elsevier Science Ltd., 1999, pp. 552-530, vol. 4, No. 12, USA.
Derian et al, “Blockage of the Thrombin Receptor Protease-Activated Receptor-1 with a Small Molecule Antagonist Prevents Thrombus and Vascular Occlusion in Non-Human Primates”, The Journal of Pharmacology and Experimental Therapeutics, 2003, pp. 855-861, vol. 304, No. 2, The American Society for Pharmacology and Experimental Therapeutics, USA.
Bevilacqua et al, “Endothelial Leukocyte Adhesion Molecule 1: An Inducible Receptor for Neurtrophils Related to Complement Regulatory Porteins and Lectins,” Science, 1989, pp.1160-1165, vol. 243.
Jalink et al, “Thrombin Receptor Activation Causes Rapid Neural Cell Rounding and Neurite Retraction Independent of Classic Sound Messengers,” The Journal of Cell Biology, 1992, pp. 411-419, vol. 118, No. 2, The Rockefeller University Press.
Hung et al, “Thrombin-induced Events in Non-Platelet Cells are Mediated by the unique Proteolytic Mechanism Established for the Cloned Platelet Thrombin Receptor,” The Journal of Cell Biology, 1992, pp. 827-832, vol. 116, No. 3, The Rockefeller University Press.
Harlan et al, “α-Thrombin Induces Release of Platelet-derived Growth Factor-like Molecule(s) by Cultured Human Endothelial Cells,” the Journal of Cell Biology, 1986, pp. 1129-1133, vol. 103, The Rockefeller University Press.
Hwang et al, “Enzyme-Catalyzed Peptide Segment Condensation Using 5 (4 H) - Oxazolones as Acyl Donors,” The American Chemical Socieity, 1993, pp. 7912-7913, vol. 115.
Ahn et al, “Structure-Activity Relationships of Pyrroloquinazolines as Thrombin Receptor Antagonists,” Bioorganic and Medicinal Chemistry Letters, 1999, pp. 2073-2078, Letters 9, Elsevier Science, Ltd.
Carney et al, “Enhancement of Incisional Wound Healing and Neovascularization in Normal Rats by Thrombin and Synthetic Thrombin Receptor-activating Peptides,” Journal of Clin Invest, 1992, pp. 1469-1477, vol. 89, The American Society or Clinical Investigation, Inc.
Malik, Asrar B., Ph.D., “Thrombin-Induced Endothelial Injury,” Seminars In Thrombosis and Hemostasis, 1986, pp. 184-196, vol. 12, No. 3, Theieme Medical Publishers, New York, NY.
Derian et al, “Blockade of the Thrombin Receptor Protease-Activated Receptor-1 with a Small-Molecule Antagonist Prevents Thrombus Formation and Vascular Occlusion in Nonhuman Primates,” The Journal of Pharmacology and Experimental Therapeutics, 2003, pp. 855-861, vol. 304, No. 2, The American Society for Pharmacology and Experimental Therapeutics, USA.
Hawkins Michael J.
Maryanoff Bruce E.
McComsey David F.
Lukton David
Ortho-McNeil Pharmaceutical , Inc.
LandOfFree
Substituted heterocyclic acyl-tripeptides useful as thrombin... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted heterocyclic acyl-tripeptides useful as thrombin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted heterocyclic acyl-tripeptides useful as thrombin... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3895330